Back to top
more

Eidos Therapeutics, Inc. (EIDX)

(Delayed Data from NSDQ)

$25.98 USD

25.98
59,460

+1.19 (4.80%)

Updated May 3, 2019 04:00 PM ET

After-Market: $25.98 (%) 5:22 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.03%
2Buy17.70%
3Hold9.37%
4Sell5.03%
5Strong Sell2.48%
S&P50011.19%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

NA

Industry: NA

Better trading starts here.

Zacks News

Alexion's (ALXN) Ultomiris IV Formulation Gets EC Approval

Alexion's (ALXN) new 100 mg/mL intravenous (IV) formulation of Ultomiris gets EC approval for PNH and aHUS.

New Strong Sell Stocks for November 5th

Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today.

New Strong Sell Stocks for November 3rd

Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today.

Alexion Plans to Raise 2020 Sales View, Buy Back $3B Shares

Alexion (ALXN) announces plans to increase its 2020 sales guidance by more than $200 million and buy back $3 billion of stock.

Company News for Oct 6, 2020

Companies in the news are: TSLA, MYOK, EIDX, GAN

New Strong Sell Stocks for September 2nd

Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today

Eidos Therapeutics (EIDX) Looks Good: Stock Adds 6.4% in Session

Eidos Therapeutics (EIDX) saw a big move last session, as its shares jumped more than 6% on the day, amid huge volumes.

Why Eidos Therapeutics (EIDX) Stock Might be a Great Pick

Eidos Therapeutics (EIDX) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

Vertex (VRTX) Hits 52-Week High, Can the Run Continue?

Vertex (VRTX) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

Eidos Therapeutics, Inc. (EIDX) Moves to Buy: Rationale Behind the Upgrade

Eidos Therapeutics, Inc. (EIDX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Alexion (ALXN) Collaborates With Stealth BioTherapeutics

Alexion (ALXN) teams up with Stealth BioTherapeutics for a late-stage therapy for mitochondrial diseases.

Alexion (ALXN) Down on News of CFO Clancy's Departure in 2019

Alexion's (ALXN) shares decline, following the news of the departure of its current chief financial officer, Paul Clancy.

Alexion (ALXN) In-licenses Amyloidosis Candidate In Japan

Alexion (ALXN) strengthens its amyloidosis portfolio with an exclusive license secured from Eidos to develop and commercialize an investigational small molecule AG10 in Japan.